The So-Called Pre-Clinical Rheumatoid Arthritis: Doubts, Challenges, and Opportunities

This publication has 27 references indexed in Scilit:

• Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects
  Drugs, 2024
• Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
  The Lancet, 2024
• Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
  The Lancet, 2024
• Rheumatoid arthritis
  The Lancet, 2023
• Synovial gene signatures associated with the development of rheumatoid arthritis in at risk individuals: A prospective study
  Journal of Autoimmunity, 2022
• Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial
  The Lancet, 2022
• The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population
  Rheumatology, 2017
• Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis
  Nature Reviews Rheumatology, 2016
• A prediction rule for the development of arthritis in seropositive arthralgia patients
  Annals of the Rheumatic Diseases, 2013
• Undifferentiated arthritis characteristics and outcomes when applying the 2010 and 1987 criteria for rheumatoid arthritis
  Annals of the Rheumatic Diseases, 2012